Claseprubart clinical trials
Also written DNTH103.
How each study uses claseprubart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the claseprubart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Dianthus Therapeutics (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test claseprubart.
- Dec 2026A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyPhase 2 · Dianthus Therapeutics
Studies
Open first, then newest update. How each study uses claseprubart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)RecruitingPhase 3Dianthus TherapeuticsNCT07647510Written as Claseprubart
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)RecruitingPhase 3Dianthus TherapeuticsNCT06858579Written as Claseprubart
- A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyActive, not recruitingPhase 2Dianthus TherapeuticsNCT06537999Written as Claseprubart
- A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)Active, not recruitingPhase 2Dianthus TherapeuticsNCT06282159Written as Claseprubart
Codes
What other systems call claseprubart · ClinicalTrials.gg INT017170
- UNII (FDA) LDW8BPL8GBCLASEPRUBARTOne source FDA
- NCI Thesaurus C216014ClaseprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LDW8BPL8GB | CLASEPRUBART | One source FDA |
| NCI Thesaurus | C216014 | Claseprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.